Drugs / PF-08032562
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07318805 | Dec 2025 → Apr 2029 expected | colorectal adenocarcinoma, female breast carcinoma, hormone receptor-positive breast cancer, triple-negative breast carcinoma | Pfizer | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-08032562 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07318805 ↗ |
| Route | Oral | “Taken by mouth (PO)” NCT07318805 ↗ |